StemExpress Statement Regarding Select Investigative Panel’s
April 20, 2016 Hearing on “The Pricing of Fetal Tissue”

StemExpress was founded in 2010 by our CEO, Cate Dyer, with just $9,000. For the first few years, all of the money StemExpress made went directly back into the company. Despite offers from investors—including large venture capital firms, private equity groups, and pharmaceutical companies—Ms. Dyer controls 100 percent of StemExpress in order to maintain the company’s focus on supporting researchers globally to produce better results for patients. Ms. Dyer believes that maintaining StemExpress as an independent company is critical to its ability to have the greatest impact on the research community.

StemExpress is dedicated to saving lives by providing researchers and research institutions specimens and products that accelerate the cure and prevention of significant medical conditions at life-changing speed. We believe that the current pace at which medical cures move to market is unacceptable, often citing the example that if a researcher discovered a cure for cancer today, it could take six to eight years to reach patients. While many researchers point to the heavy restrictions placed on research by regulatory agencies, the slow timeframe is overwhelmingly due to the amount of time it takes to source specimens, blood samples, and tissue needed for proper due diligence that is required by regulatory agencies. As a central source for research material, StemExpress is able to support hundreds of researchers at the same time. This allows StemExpress to make a positive and direct impact reducing human suffering around the globe.

I. StemExpress’s Business Structure

StemExpress is a for-profit company but that does not mean that every product provided to researchers or research institutions is for profit. Some products are provided to clients for profit while other products are provided at cost or at a loss. Fetal tissue and cord blood are both provided at a loss. StemExpress has never profited—or received “valuable consideration” —from the provision of fetal tissue. It is also important to note that there are substantial expenses associated with running a business like StemExpress—some exemplar costs include (i) procuring blood and tissue for use in the manufacturing of isolated cells (including salaries and supplies); (ii) running our laboratory and manufacturing isolated cells (including salaries for highly trained staff and extremely expensive equipment); (iii) marketing and sales operations; and (iv) other general and administrative expenses.

II. StemExpress’s Support for Fetal Tissue Research

Simply because StemExpress is a for-profit company does not mean that we do not participate in extensive philanthropic activities that result in no profit for the company. One example of this philanthropic activity is our support for fetal tissue research. As discussed in greater detail herein, the provision of fetal tissue is not only unprofitable, StemExpress incurs substantial financial losses in order to support the provision of fetal tissue. While most researchers
StemExpress Statement Regarding Select Investigative Panel’s
April 20, 2016 Hearing on “The Pricing of Fetal Tissue”

working with fetal tissue or fetal cells also use adult human blood or tissue in their research, they consistently report better results in their work using fetal tissue. Researchers are generally aware that the use of fetal tissue may be controversial, so the choice to use fetal tissue is driven solely by the greater potential for scientific breakthroughs. There are also groups and individual activists that would prefer animals not be used in research. Both groups have large activist bases and have a history of causing significant harm to research institutions and individual researchers through laboratory bombings, harassment, harm to reputation, death threats, and even death. We know of no company, researcher, or scientist who does not think carefully and cautiously before deciding to use controversial material, tissue or cells in their work.

A good example of the research community specifically seeking fetal tissue is in response to the Zika virus.1 The Centers for Disease Control and National Institutes of Health have publicly expressed the need to examine fetal tissue to determine how the Zika virus affects the fetus in the womb causing fetal brain damage and a study was recently published in the New England Journal of Medicine.2 During the same period of time in which Congress has increased its criticism of fetal tissue research—and expressed doubt as to its practical implications—the Zika virus has become a global epidemic, spreading now to the United States. Many researchers throughout the medical community have shared with StemExpress that their institutions are waiting for the Select Panel to complete its investigation before going forward with additional fetal tissue research specific to the Zika virus and potential treatments.

III. Comparison to Organ Procurement Organizations

As a blood and tissue procurement organization, StemExpress modeled its tissue procurement operations after organ procurement organizations (OPOs). Like OPOs, StemExpress must either source tissue from hospitals and clinics or develop partnerships with entities where the company’s personnel could be on the ground and perform the procurement role directly. Unlike OPOs, however, StemExpress does receive any reimbursement from Medicare for the procurement of cadaveric tissue. In contrast, OPOs receive substantial reimbursement on the basis of potential transplantation, regardless of whether transplant even takes place.

1 Alex Zielinski, Fetal Tissue Research Uncovers New Information About Zika, THINKPROGRESS (Mar. 31, 2016), http://thinkprogress.org/health/2016/03/31/3765233/fetal-tissue-zika-study/.

StemExpress Statement Regarding Select Investigative Panel’s
April 20, 2016 Hearing on “The Pricing of Fetal Tissue”

One tragic example that illustrates the difference between fetal and human tissue procurement is that of a mother donating her infant’s organs in April 2014. The infant was less than one-hour old. In this case, the mother consented, the organs were collected by a for-profit limited liability company in North Carolina and liver cells were isolated from the donated liver. Because this was a live birth, if only for less than one hour, this procurement was handled by an OPO and likely resulted in thousands of dollars of “reimbursements.”

In most cases, if a tissue is “capable” at the time of collection of being transplanted, the payer will reimburse the procurement company, even if it turns out that tissue was not transplanted. On average those reimbursements are paid per organ or tissue and range from $20,000-$50,000 per specimen. These charges are assessed for transplantable organs, even if it is later determined that the tissue cannot be transplanted and the organ is sold for research purposes only. In comparison, the reimbursable fee paid by StemExpress of roughly $50-$75 per product of conception or organ that StemExpress provides back to the institutions involved in the procurement is drastically less than what would considered “normal” and reimbursed by the payers—either public or private—in the OPO transplant world.

IV. StemExpress’s Pricing of Fetal Tissue

When StemExpress was partnered with Planned Parenthood affiliates and in California, we had phlebotomists and other tissue procurement professionals on the ground in various clinics “on deck” to handle procurement based on the specific needs of our customers in research and industry. For example, procurement technicians were paid roughly $10-15/hour as “base” compensation and paid additional compensation based on the volume of blood or tissue procurement. Given the unpredictable nature of tissue procurement, a procurement technician could often spend a full day at a clinic and collect no tissues. Regardless of the whether we had 10 customer requests for a week or 50, we had to maintain staffing at clinics and incur that labor costs on a weekly basis. To the extent that a customer had a particularly difficult request—e.g., tissue from a mother with a particularly rare disease—we might have had a procurement technician staffed at a clinic for weeks or months, waiting for that particular characteristic to meet the needs of the researcher. He or she would perform blood draws and be involved in other tissue procurement during this time.


This labor overhead cost is a just one part of the overall cost and expenses that are incurred in the procurement of fetal tissue, which includes reasonable costs for processing, preservation, quality control, transportation, and storage of fetal tissue. Estimates of the total costs and expenses associated with the procurement of fetal tissue are detailed in Table A, below. These estimated costs—modeled on StemExpress technicians being in the clinics—includes the approximately $55 reimbursement that was paid to clinics for clinic staff time and use of space for consenting patients, obtaining blood draws, evaluating tissue, and storing procurement and shipping materials.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Procurement Manager labor</strong></td>
<td>Receive and evaluate purchase order, enter into company system and task board, assign to clinics</td>
<td>1 hour x $35</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td><strong>Packaging supplies</strong></td>
<td>Packaging all supplies needed for procurement</td>
<td>1 hour x $10</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td><strong>FedEx</strong></td>
<td>Supplies to clinic</td>
<td>N/A</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td><strong>Mileage</strong></td>
<td>Mileage paid to technician (.56/mile)</td>
<td>N/A</td>
<td>$142.00</td>
<td>$142.00</td>
</tr>
<tr>
<td><strong>Supply cost</strong></td>
<td>Box, conical tube, media, petri dish, labels, biohazard bag, gel packs, etc.</td>
<td>N/A</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td><strong>Technician labor</strong></td>
<td>Patient consent, procurement, paperwork, packaging</td>
<td>8 hours x $10</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td><strong>Technician compensation</strong></td>
<td>Technician compensation</td>
<td>N/A</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td><strong>Clinic Reimbursement</strong></td>
<td>Staff time, technician space, storage of supplies, blood draw chair usage, consent space</td>
<td>N/A</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td><strong>Infectious disease draw</strong></td>
<td>Supplies: tubes, labels, needle, biohazard bag, etc</td>
<td>N/A</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td><strong>Infectious disease screening</strong></td>
<td>Screening for HIV, HepB, HepC, LCMV</td>
<td>N/A</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td><strong>Shipping Charges</strong></td>
<td>Average Shipment cost to the lab</td>
<td>N/A</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td><strong>Procurement Manager labor</strong></td>
<td>Review paperwork, communications with courier, communications with researcher</td>
<td>1 hour x $35</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td><strong>Product Receipt</strong></td>
<td>Receipt of product at front desk, check into company system, check into log</td>
<td>1 hour x $15</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td><strong>Inventory &amp; Supply Management</strong></td>
<td>Prorated stores management</td>
<td>1 hour x $20</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td>$732.00</td>
<td>$732.00</td>
</tr>
</tbody>
</table>

These costs and expenses are an estimate, but are conservative in that no general overhead costs or any specific overhead, such as obtaining consent forms approved by an Independent Review Board (IRB), is included. These costs and expenses could also increase dramatically for a rare procurement that requires substantially more idle labor costs awaiting viable tissue.

Despite knowing that providing fetal tissue was going to result in financial losses, StemExpress has consistently charged less than non-profit entities that provide fetal tissue, as well.
V. StemExpress Revenue and Costs Associated with Fetal Tissue

The majority of StemExpress’s business involves isolating and purifying cells derived from donated tissue and blood. An exceedingly small portion of the company’s revenue is derived from the provision of fetal tissue. For example, over the past several years revenue derived from fetal tissue has constituted roughly 1% of the company’s total revenue before accounting for costs and expenses. Taking into account these cost and expenses, StemExpress operates in the red providing fetal tissue. From 2014 to 2015, StemExpress collected $74,955 in gross revenue from providing fetal tissue but incurred an estimated $95,160 in costs and expenses related to the processing, preservation, quality control, transportation, and storage of fetal tissue. The financial impact of these substantial costs is a two-year loss estimated at $20,205 on providing fetal tissue to clients. See Table B (below). The costs and expenses for 2011 through 2013 similarly exceed revenue, so StemExpress has always supported fetal tissue research at a financial loss.

### Table B: StemExpress Fetal Tissue Revenue v. Estimated Costs/Expenses (2014-2015)

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2015</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal Tissue Revenue (Actual)</td>
<td>$49,280.00</td>
<td>$25,675.00</td>
<td>$74,955.00</td>
</tr>
<tr>
<td>Fetal Tissue Costs/Expenses (Est.)</td>
<td>$62,220.00</td>
<td>$32,940.00</td>
<td>$95,160.00</td>
</tr>
<tr>
<td>Loss Incurred Supporting Fetal Tissue Research (Est.)</td>
<td>$(12,940.00)</td>
<td>$(7,265.00)</td>
<td>$(20,205.00)</td>
</tr>
</tbody>
</table>

Some may ask why would we offer any service/product at a loss, and the answer is our mission statement – StemExpress accelerates the cure and prevention of significant medical conditions at life changing speed.

VI. StemExpress’s Consent and Audit History

While the specific requirements for consent for fetal tissue donation vary from state to state, StemExpress utilizes consent forms approved by an Independent Review Board (“IRB”) as a matter of course due to the high standards expected by our research customers. Unless specifically requested by a clinic or hospital to use an alternative informed consent form, StemExpress utilizes our own IRB-approved consents. We work with the clinics and other
StemExpress Statement Regarding Select Investigative Panel’s
April 20, 2016 Hearing on “The Pricing of Fetal Tissue”

locations where we collect and procure blood and tissue to encourage them to default to our IRB-approved consent forms.

StemExpress is also the subject of regular audits, which is considered routine in the life sciences and biotech industries. In 2014, the U.S. Food and Drug Administration (“FDA”) audited StemExpress and found no issues or violations in our practices. Despite the “all-clear” from the FDA, StemExpress was asked to deregister with the FDA because their oversight is limited to transplantable grade or clinical grade organizations, not procurement organization like StemExpress.

Our clients regularly audit us, as well, applying standards that vary from institution to institution. Some clients are ISO.9000 certified and some are not. Some have FDA oversight and some do not. We also work with international clients that are subject to unique country-specific laws. StemExpress has regularly defaulted to the high standards of federal agencies like the FDA and HHS to adopt best practices that set the standard for the tissue procurement industry.
The current outbreak of Zika virus (ZIKV) infection has been associated with an apparent increased risk of congenital microcephaly. We describe a case of a pregnant woman and her fetus infected with ZIKV during the 11th gestational week. The fetal head circumference decreased from the 47th percentile to the 24th percentile between 16 and 20 weeks of gestation. ZIKV RNA was identified in maternal serum at 16 and 21 weeks of gestation. At 19 and 20 weeks of gestation, substantial brain abnormalities were detected on ultrasonography and magnetic resonance imaging (MRI) without the presence of microcephaly or intracranial calcifications. On postmortem analysis of the fetal brain, diffuse cerebral cortical thinning, high ZIKV RNA loads, and viral particles were detected, and ZIKV was subsequently isolated.

Zika virus (ZIKV), a mosquito-borne flavivirus and member of the Flaviviridae family, was originally isolated from a sentinel primate in Uganda in 1947.1 ZIKV was associated with mild febrile disease and maculopapular rash in tropical Africa and some areas of Southeast Asia. Since 2007, ZIKV has caused several outbreaks outside its former distribution area in islands of the Pacific: in 2007 on Yap island in Micronesia, in 2013 and 2014 in French Polynesia, and in 2015 in South America, where ZIKV had not been identified previously.2-5 There are separate African and Asian lineages of the virus,6 and the latter strains have caused the outbreaks in the Pacific and the Americas.7 As in the transmission of dengue and chikungunya viruses, the main transmission cycle of ZIKV occurs between urban aedes mosquitoes and humans.

One striking feature of the current ZIKV outbreak is the apparent increased risk of intrauterine or perinatal transmission of the virus as well as the marked increase in the number of newborns with microcephaly reported in Brazil.6-17 A recent prospective study showed fetal ultrasonographic abnormalities in 12 of 42 women (29%) with ZIKV infection during pregnancy; 7 of the 42 fetuses (17%) that were studied had microcephaly, cerebral atrophy, or brain calcifications.18 Because of the association between ZIKV infection and microcephaly and other neurologic disorders, the World Health Organization has declared the ZIKV epidemic a public health emergency of international concern.13

Early in this particular outbreak, investigations into the viral pathogenesis, vertical transmission rates, potential viral cofactors, and sensitivity and specificity of diagnostic testing have presented more questions than answers. Nevertheless,
The Centers for Disease Control and Prevention (CDC) has issued a travel advisory for pregnant women, as well as guidelines for health providers caring for all travelers from affected regions. The CDC recommends that pregnant women with a history of travel to an area in which ZIKV is endemic should undergo ZIKV serologic testing and fetal ultrasonography to screen for microcephaly or intracranial calcifications. For a diagnosis of fetal ZIKV infection, RNA detection in amniotic fluid may be considered in pregnant women with positive results on ZIKV serologic testing. Here we present a report of a case of congenital ZIKV infection and subsequent findings in a pregnancy that was terminated at 21 weeks of gestation.

**Case Report**

A 33-year-old Finnish woman who was in the 11th week of gestation was on holiday in Mexico, Guatemala, and Belize with her husband in late November 2015. (Details are provided in Section 1.0 of the Supplementary Appendix, available with the full text of this article at NEJM.org.) During their travels, she and her husband recalled being bitten by mosquitoes, particularly in Guatemala. One day after her arrival at her current residence in Washington, D.C., she became ill with ocular pain, myalgia, and mild fever (maximum, 37.5°C), which lasted for 5 days. On the second day of fever, a rash developed (Fig. 1, and Fig. S5 in the Supplementary Appendix). Serologic analysis that was performed 4 weeks after the onset of illness while she was on a trip to her native Finland was positive for IgG antibodies and negative for IgM antibodies against dengue virus. One day after her arrival at her current residence in Washington, D.C., she became ill with ocular pain, myalgia, and mild fever (maximum, 37.5°C), which lasted for 5 days. On the second day of fever, a rash developed (Fig. 1, and Fig. S5 in the Supplementary Appendix). Her husband was concomitantly reporting similar symptoms. Serologic analysis that was performed 4 weeks after the onset of illness while she was on a trip to her native Finland was positive for IgG antibodies and negative for IgM antibodies against dengue virus. Subsequent serologic analysis was positive for both IgG and IgM antibodies against ZIKV, findings that were compatible with acute or recent ZIKV infection. Serologic analysis for the presence of chikungunya virus was negative. The patient had been vaccinated against tick-borne
encephalitis and yellow fever more than 10 years earlier.

Fetal ultrasonography that was performed at 13, 16, and 17 weeks of gestation (1, 4, and 5 weeks after the resolution of symptoms) showed no evidence of microcephaly or intracranial calcifications. However, there was a decrease in the fetal head circumference from the 47th percentile at 16 weeks to the 24th percentile at 20 weeks.

At 16 weeks of gestation, the presence of flavivirus in serum was detected on nested reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay, and sequencing showed identity to Central American epidemic strains of ZIKV. The finding was confirmed with a specific ZIKV quantitative RT-PCR assay (Table S2 in the Supplementary Appendix). The Division of Vector-Borne Diseases Arbovirus Diagnostic Laboratory at the CDC reported serologic evidence of infection at 17 weeks of gestation, with serum positivity for ZIKV IgM and a titer of more than 1:2560 on a plaque-reduction neutralization test. On the basis of these results, the patient sought more thorough assessment of the fetus.

Fetal ultrasonography at 19 weeks of gestation showed abnormal intracranial anatomy (Fig. 2, and Fig. S1 in the Supplementary Appendix). The cerebral mantle appeared to be thin with increased extra-axial spaces. Both frontal horns were enlarged with heterogeneous, predominantly echogenic material present in the frontal horn and body of the left lateral ventricle, a finding that raised concern about intraventricular hemorrhage. Dilation and upward displacement of the third ventricle, dilation of the frontal horns of the lateral ventricles, concave medial borders of the lateral ventricles, and the absence of the cavum septum pellucidum suggested agenesis of the corpus callosum. No parenchymal calcifications were seen. The head circumference measured in the 24th percentile for gestational age. The remainder of the fetal anatomy was normal.

Fetal MRI at 20 weeks of gestation showed diffuse atrophy of the cerebral mantle, which was most severe in the frontal and parietal lobes, with the anterior temporal lobes least affected (Fig. 3). The normal lamination pattern of the cerebral mantle was absent, and the subplate zone was largely undetectable. The corpus callosum was significantly shorter than expected for gestational age, with an anterior–posterior length of 14 mm (expected range, 18 to 22). The cavum septum pellucidum was very small. The lateral ventricles were mildly enlarged, as was the third ventricle, with a transverse diameter measuring 2.5 mm (average measurement at gestational age, 1.75 mm [range, 1.1 to 2.3]).

The fourth ventricle was normal. The volume of the choroid plexus was unusually prominent, without evidence of hemorrhage. No focal destructive lesions were identified within the cerebral cortex or white matter. The cerebellum was normal in appearance and size. Given the grave prognosis,
Figure 3. Magnetic Resonance Imaging of the Fetal Brain at 19 Weeks of Gestation.

On T2-weighted imaging of the brain of the ZIKV-exposed fetus, a 3-mm-thick axial view (Panel A) shows severe atrophy of the cerebral mantle, which was most visible in the frontal regions (arrows) where the cortical mantle measures 1.4 mm. In a 2-mm-thick midline sagittal image (Panel B), the small corpus callosum (arrows) is visible, with an anterior–posterior length of 14 mm (normal range, 18 to 22).18,19. Below are matching images of the same locations and thicknesses in a normal fetus with a gestational age of 20 weeks 3 days, showing the cortical mantle measuring 8 mm (in Panel C) and the corpus callosum measuring 20 mm (in Panel D).
the patient elected to terminate the pregnancy at 21 weeks of gestation.

METHODS

We tested samples obtained from the patient, her spouse, and the fetus and from viral isolation trials for ZIKV RNA using nested pan-flavivirus RT-PCR and quantitative RT-PCR for ZIKV. Levels of ZIKV IgM, IgG, and neutralizing-antibody titers were determined by means of standard methods. We performed immunohistochemical and electron microscopic analyses to study fetal brain tissue. Viral isolation trials using the patient’s serum and fetal tissues were performed with the use of SK-N-SH human neuroblastoma cells, Vero E6 green monkey kidney cells, and C6/36 Aedes albopictus mosquito cells. We used next-generation sequencing and Bayesian analysis to study the genetics of the ZIKV strain isolate. Additional details about the analyses are provided in the Methods section of the Supplementary Appendix.

RESULTS

FETAL NEUROLOGIC ABNORMALITIES

A postmortem examination was performed with materials collected for additional study. Gross examination showed normal fetal anatomy and severe autolysis. The brain weighed 30 g (reference weight, 49±1520) and showed no apparent gross abnormalities. Microscopic analysis revealed abundant apoptosis primarily affecting the intermediate differentiated postmigratory neurons in the neocortex (Fig. 4, and Fig. S2 in the Supplementary Appendix). Early mineralization was seen in association with apoptotic neurons focally. In contrast, the well-differentiated neurons of the basal ganglia and limbic regions as well as primitive cells in the germinal matrix appeared to be unaffected.

In addition to the cortical neuronal abnormalities, the subventricular zone and white matter showed severe volume loss with extensive axonal rarefaction and macrophage infiltrates (Fig. 4). This pattern correlates with the atrophy of the subplate seen on prenatal imaging. There was diffuse infiltration of macrophages in the cerebral cortex, subventricular zone, white matter, and leptomeninges but not in the germinal matrix of the ganglionic eminence. Scattered loose microglial aggregates were observed in the deep gray matter and brain stem, but there was no evidence of well-formed microglial nodules or other classic histologic features of viral encephalitis, such as perivascular inflammatory infiltrates, viral inclusions, or ventriculitis. Ultrastructural examination of fixed cortical tissue showed a rare aggregate of intracellular electron-dense, viral-like particles that measured 39 to 41 nm in diameter (mean, 40.26). Our ability to specifically localize the cellular compartment housing the particles was limited by poor tissue preservation, but the morphologic features and size of this structure were similar to those reported by Mlakar et al. and the CDC. The choroid plexus was focally enlarged and edematous, with scant hemosiderin deposits, which may appear to be similar to intraventricular hemorrhage on prenatal imaging. Histologic examination of the eyes, spinal cord gray matter, dorsal root ganglia, and spinal nerves did not reveal overt microscopic abnormalities. Spinal white-matter tracts were not well visualized. A detailed pathological description of the brain and other organs is provided in the Methods section of the Supplementary Appendix.

FETAL AND MATERNAL ZIKV VIRAL LOADS

The highest ZIKV viral loads were found in fetal brain, with substantial viral loads in the placenta, fetal membranes, and umbilical cord, as studied on quantitative RT-PCR (Table S2 in the Supplementary Appendix). Lower amounts of ZIKV RNA were found in fetal muscle, liver, lung, and spleen. Amniotic fluid that was obtained at the time of termination was positive for ZIKV RNA with low viral counts. On PCR assays to detect DNA, the amniotic fluid was negative for parvovirus B19, herpes simplex virus types 1 and 2, cytomegalovirus (CMV), and Toxoplasma gondii, and the fetal brain tissue was negative for herpes simplex virus types 1 and 2 and varicella–zoster virus.

Maternal serum that was obtained on the day before termination was also positive for ZIKV RNA with a low viral count (2.1x10^3 copies per milliliter). No ZIKV RNA was detected in the serum, peripheral-blood mononuclear cells, saliva, or urine in samples obtained 11 days and 13 days after termination. On IgM analysis, the mother had no evidence of serum antibodies indicating acute infection with CMV, parvovi-
russ B19, *T. gondii*, or rubella virus. Samples obtained from her spouse were all negative for ZIKV RNA, including urine (obtained 11 weeks after travel), serum (obtained 5 and 11 weeks after travel), and semen (obtained 10 and 12 weeks after travel), although results of testing for ZIKV IgG (titer 320) and IgM (titer 20) were positive.

Figure 4. Neuropathological Features of Fetal ZIKV Infection.

In postmortem analyses of samples obtained from the fetus, an area of parietal cortex has abundant apoptotic neurons (Panel A), with detail shown in the inset view. The unaffected occipital cortex is thicker than the parietal cortex (Panel B), as indicated by the vertical bars. The basal ganglia (striatum) appears to be morphologically normal (Panel C), and cells in the germinal matrix of the ganglionic eminence are histologically normal (Panel D). White matter shows extensive axonal rarefaction and infiltrates of macrophages containing foamy cytoplasm and cellular debris in some cells (Panel E) (hematoxylin and eosin staining in Panels A through E). Panel F shows macrophage infiltrates in the cortex (area above the dashed line) and subcortical white matter (area below the dashed line) (anti-CD68 immunostaining with hematoxylin counterstaining). The inset shows possible viral-like particles within a subcellular compartment, as seen on electron microscopy.
**Virus Isolation**

ZIKV replication was detected as an increase in ZIKV RNA on quantitative RT-PCR assay of SK-N-SH and Vero E6 cells inoculated with the fetal brain sample. The quantities of ZIKV RNA increased rapidly in the SK-N-SH cells after the first day of inoculation, whereas in the Vero E6 cells, viral RNA loads started to increase on day 4 after inoculation. Viral replication was not detected in cells inoculated with other samples. The tissue-inoculated SK-N-SH and Vero E6 cells were further shown to express ZIKV antigens by reactivity with human convalescent anti-ZIKV serum (obtained from the father of the fetus) on immunofluorescence staining and to produce flavivirus-like particles, as seen on electron microscopy (Fig. 5).

A complete ZIKV genome was sequenced from supernatant of SK-N-SH cells on day 5 after inoculation. Phylogenetic analysis indicated that the viral strain (designated ZIKV_FB-GWUH-2016; GenBank number, KU870645) was a member of the Asian genotype and closely related to two ZIKV sequences obtained from Guatemalan patients who presented with mild illness (Fig. 6, and Fig. S6 in the Supplementary Appendix). The FB-GWUH-2016 strain had 23 to 51 nucleotide differences and 8 to 14 amino acid differences as compared with the ZIKV strains detected previously in the Americas (99.6 to 99.8% identities) (Fig. 5D). Five of the eight differences in amino acids between FB-GWUH-2016 and the Guatemalan strains were specific for the FB-GWUH-2016 strain (i.e., differences that were not detected in other ZIKV strains sequenced so far). One amino acid substitution was a reversion toward the African ZIKV genotype. Three amino acid substitutions were common for FB-GWUH-2016 and the Guatemalan strains but distinct from all other reported ZIKV strains.

**Discussion**

The current recommendations for ZIKV diagnostic practices are based on the understanding that ZIKV viremia lasts for less than a week after the onset of infection. During the week of symptomatic infection, RNA detection in serum or blood is considered to be the diagnostic method of choice. ZIKV RNA can be detected in urine for some days longer. ZIKV is also present in semen for an unknown length of time, and scattered reports of sexual transmission of ZIKV have emerged. ZIKV RNA testing is not recommended for pregnant women after the first week after the onset of clinical disease. The diagnosis is usually based on a ZIKV-specific antibody response with higher IgM and neutralizing-antibody responses to ZIKV than to other flaviviruses. However, we have detected ZIKV RNA in the serum of a pregnant woman at 4 weeks and 10 weeks after the clinical onset of ZIKV infection but not after delivery. We suspect that the persistent ZIKV viremia in the patient described here was a consequence of viral replication in the fetus or placenta, which had high viral loads. Therefore, in addition to current ZIKV diagnostics, the use of quantitative RT-PCR methods may be a potential diagnostic approach for ongoing placental or fetal infections in pregnant women. Notably, in this patient, the ZIKV RNA levels were slightly higher in the maternal serum than in the amniotic fluid. The dynamics of ZIKV RNA in the serum of infected pregnant women are not well understood and will need to be assessed in larger studies.

It is estimated that 80% of ZIKV infections are asymptomatic. Although the evidence of the association between the presence of ZIKV in pregnant women and fetal brain abnormalities continues to grow, the timing of infection during fetal development and other factors that may have an effect on viral pathogenesis and their effects on the appearance of brain abnormalities on imaging are poorly understood. Oliveira Melo et al. described two cases of ZIKV intrauterine infection associated with microcephaly and brain calcifications that were diagnosed by means of ultrasonography during the third trimester. Similar to the fetus in our report, the two fetuses in that study showed abnormal development of the corpus callosum and decreased brain parenchymal volume. In the case described by Mlakar et al., the results of ultrasonography that was performed at 14 weeks and 20 weeks of gestation were normal, but microcephaly, ventriculomegaly, and calcifications were seen on ultrasonography at 29 weeks of gestation. In the larger Brazilian cohort, cerebellar atrophy was seen in a fetus at 20 weeks of gestation, but microcephaly was not diagnosed until 27 to 35 weeks in their cohort. In our study, a review of three sequential ultrasonographic images between 16 and 20 weeks showed a decrease in the fetal head circumferences from the 47th percentile to the 24th percentile, which suggests a reduction in the rate of
brain growth during that period (Fig. S3 in the Supplementary Appendix). We suspect these reductions in brain growth would have eventually met the criteria for microcephaly. As this case shows, the latency period between ZIKV infection of the fetal brain and the detection of microcephaly and intracranial calcifications on ultrasonography is likely to be prolonged. Negative ultrasonographic studies during this period would be falsely reassuring and might delay critical time-sensitive decision making. Serial ultrasonographic measurements of head circumference may provide useful predictive information. The superior soft-tissue resolution of fetal brain MRI might be more sensitive to developmental and encephaloclastic changes, thereby expediting the detection of evolving fetal brain anomalies.

This case is an early foray into the histopathological findings associated with ZIKV in the midgestational fetal brain. The overwhelming findings were of loss of intermediately differentiated postmigratory neurons through an apoptotic mechanism. There appeared to be preservation of more differentiated neurons in basal ganglia, limbic region, and dorsal spinal cord. The germinal matrix cells also appeared to be spared.

**Figure 5.** Isolation of ZIKV from Fetal Brain Tissue, ZIKV Growth in Fetal Tissues, Electron Microscopy of a Flavivirus-like Particle, and Amino Acid Differences in the Newly Isolated Strain.

Panel A shows immunofluorescence assays of human neuroblastoma cells (SK-N-SH) and Vero E6 cells that were inoculated with fetal tissue samples to determine the presence of ZIKV. The samples were shown to express ZIKV antigens by reactivity with human convalescent anti-ZIKV serum (ZIKV IgG-positive and IgG-negative [control] samples; dilution, 1:40) obtained from the father. Antihuman IgG fluorescein isothiocyanate conjugate was used as a reagent. Panel B shows the growth curve of ZIKV in SK-N-SH and Vero E6 cells on RT-PCR, indicating the change in ZIKV RNA loads (as determined by the change in cycle threshold) in cell cultures after inoculation with samples from fetal brain, spleen, membrane and cord, and placenta. Panel C shows an electron microscopic image of a particle resembling a flavivirus from supernatant of SK-N-SH cells inoculated with fetal brain tissue. Panel D shows amino acid differences between the FB-GWUH-2016 isolate of ZIKV in this study and the related Guatemalan ZIKV strains (red arrows) and the amino acids that were identical in the study isolate and the related strains but distinct from all other known epidemic strains (blue arrows).
Of note, the germinal matrix consists predominantly of glioblasts at midgestation with the majority of the neuroblasts having already migrated out of the zone. Although we could not evaluate neuronal precursor subtypes other than calretinin-expressing interneuron lineage cells, selective neuronal vulnerability to ZIKV injury requires further investigation.

The successful isolation of infectious ZIKV from human fetal brain fulfills Koch’s second postulate regarding the isolation of pathogens from a diseased organism and strengthens the association between congenital ZIKV infection and fetal brain damage. Although ZIKV RNA was found in several fetal organs and the placenta, the virus could be isolated only from brain tissue. The rapid isolation in a human neuroblastoma cell line suggests a predilection of the ZIKV strain for human neural lineage cells. This hypothesis is in line with the histopathological findings and the results of a recent study showing a high rate of ZIKV infection in cortical neural progenitor cells but not in embryonic or pluripotent stem cells.30 The close genetic relationship between the isolate in our report and Guatemalan ZIKV strains was consistent with the anamnestic knowledge on the likely geographical origin of the infection. We found a relatively high frequency of nonsynonymous mutations between the FB-GWUH-2016 genome and the Guatemalan ZIKV genome (Fig. S4 in the Supplementary Appendix), a finding that could indicate viral adaptation to growth in the fetal brain. However, no amino acid changes were identical to previously reported alterations in the ZIKV genome sequenced from fetal brain tissue.30

In conclusion, our study highlights the possible importance of ZIKV RNA testing of serum obtained from pregnant women beyond the first week after symptom onset, as well as a more detailed evaluation of the fetal intracranial anatomy by means of serial fetal ultrasonography or fetal brain MRI. The isolation of ZIKV from fetal brain provides additional evidence for the association between congenital ZIKV infection and fetal brain damage and provides tools for further studies of the pathogenesis of ZIKV-induced microcephaly. Future studies at various gestational ages will offer better insight into the role of ZIKV infection in abnormal brain development and provide markers for its detection.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the patient and her husband for their support of our study; Irena Suomalainen, Inkeri Luoto, and Sanna Mäki of the University of Helsinki for their technical assistance; Tamas Baszinka and Kirsi Aaltonen for their help in preparing samples; Dr. Eili Huhtamo for guidance in setting up the nested RT-PCR assay; the Finnish IT Center for Science for the allocation of computational resources; and Yvette Veloso, Mandy Field, and Laurie King for their technical support.

APPENDIX

The authors’ full names and academic degrees are as follows: Rita W. Driggers, M.D., Cheng-Ying Ho, M.D., Ph.D., Essi M. Korhonen, M.Sc., Suvi Kuivamäki, M.Sc., Anne J. Jääskeläinen, Ph.D., Teemu Smura, Ph.D., Avi Rosenberg, M.D., Ph.D., D. Ashley Hill, M.D., Roberta L. DeBiasi, M.D., Gilbert Vezina, M.D., Julia Timofeev, M.D., Fausto J. Rodriguez, M.D., Lev Levanov, Ph.D., Jennifer Razak, M.G.C., C.G.C, Preetha Iyengar, M.D., Andrew Hennenfent, D.V.M., M.P.H., Richard Kennedy, M.D., Robert Lanciotti, Ph.D., Adre du Plessis, M.B., Ch.B., M.P.H., and Olli Vapalahti, M.D., Ph.D.

The authors’ affiliations are as follows: the Department of Gynecology and Obstetrics, Division of Maternal Fetal Medicine (R.W.D., J.T.), and the Department of Pathology (F.J.R.), Johns Hopkins University School of Medicine, Baltimore; the Division of Maternal Fetal Medicine, University Hospitals, Cleveland, Ohio (C.Y.H.), and the Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland (E.M.K.).

The Authors’ affiliations are as follows: the Department of Gynecology and Obstetrics, Division of Maternal Fetal Medicine (R.W.D., J.T.), and the Department of Pathology (F.J.R.), Johns Hopkins University School of Medicine, Baltimore; the Division of Maternal Fetal Medicine, University Hospitals, Cleveland, Ohio (C.Y.H.), and the Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland (E.M.K.).

The authors report no financial relationships with commercial interests.

Figure 6. Phylogenetic Tree Showing Newly Isolated ZIKV Strain.
The FB-GWUH-2016 ZIKV strain that was isolated in the fetal brain in this case report is shown at the top of a phylogenetic tree, which was constructed with the use of the Bayesian Markov chain Monte Carlo method. A sub-clade of Asian lineage that contains the American ZIKV strains is shown. Viral strains are listed according to country and year of collection. The scale bar shows the nucleotide sequence divergence. An expanded phylogenetic tree showing the complete coding regions of ZIKV strains (as of February 28, 2016) is provided in Fig. S6 in the Supplementary Appendix.
Medicine, Sibley Memorial Hospital (R.W.D., J.T., J.R.), the Division of Pathology and Center for Genetic Medicine Research (C.-Y.H., A.R., D.A.H.), Division of Pediatric Infectious Diseases (R.L.D.), Department of Diagnostic Radiology and Imaging (G.V.), and the Fetal Medicine Institute, Division of Fetal and Transitional Medicine (A.P.), Children’s National Health System, the Departments of Integrative Systems Biology (C.-Y.H., D.A.H.), Pediatrics and Microbiology, Immunology and Tropical Medicine (R.L.D.B.), and Radiology and Pediatrics (G.V.), George Washington University School of Medicine and Health Sciences, the Center for Policy, Planning and Evaluation (P.L.) and Centers for Disease Control and Prevention (CDC)—Council of State and Territorial Epidemiologists (CSTE) Applied Epidemiology Fellowship (A.H.), District of Columbia Department of Health, and One Medical Group (R.K.) — all in Washington, DC; the Departments of Virology (E.M.K., S.K., T.S., L.L., O.V.) and Veterinary Biosciences (E.M.K., O.V.), University of Helsinki, and the Department of Virology and Immunology, University of Helsinki and Helsinki University Hospital (A.J.J., O.V.), Helsinki; and the Arboviral Diseases Branch, Division of Vector-Borne Diseases, National Center for Emerging Zoonotic Infectious Diseases, CDC, Atlanta (R.L.).

REFERENCES

17. CDC health advisory: recognizing, managing, and reporting Zika virus infections in travelers returning from Central America, South America, the Caribbean and Mexico. Atlanta: Centers for Disease Control and Prevention, 2016 (http://emergency.cdc.gov/han/han03985.asp).
26. McCarthy M. Zika virus was transmitted by sexual contact in Texas, health officials report. BMJ 2016;352:i720.

Copyright © 2016 Massachusetts Medical Society.